4McCowen KC,MalhotraA,Bistrian BR. Endocrine and metabolic dysfunction syndromes in the critically ill[J].{H}CRITICAL CARE CLINICS,2001,(01):107.
5Bode BW,Steed RD,Davidson PC. Reduction in severe hypoglycemia with long term continuous subcutaneous insulin in type 1 diabetes[J].{H}DIABETES CARE,1996,(04):324.
6Hamann A,Matthaei S,Rosak C. A randomized clinical trial comparing breakfast,dinner,or bedtime administration of insulin glargine in patients with type 1 diabetes[J].{H}DIABETES CARE,2003,(06):1738-1744.
7LeporeM,Pampanelli S,Fanelli C. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine,NPH insulin,and ultralente human insulin and continuous subcutaneous in fusion of insulin lispro[J].{H}DIABETES,2000,(12):2142-2148.
